Research programme: anti-cancer multabodies therapeutics - Radiant Biotherapeutics
Latest Information Update: 05 Mar 2024
At a glance
- Originator Radiant Biotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Feb 2024 Preclinical trials in Cancer in Canada (Parenteral), prior to February 2024 (Radiant Biotherapeutics pipeline, February 2024)